MA50423A - Procédés de traitement de tumeurs solides au moyen d'antagonistes du ccr2 - Google Patents

Procédés de traitement de tumeurs solides au moyen d'antagonistes du ccr2

Info

Publication number
MA50423A
MA50423A MA050423A MA50423A MA50423A MA 50423 A MA50423 A MA 50423A MA 050423 A MA050423 A MA 050423A MA 50423 A MA50423 A MA 50423A MA 50423 A MA50423 A MA 50423A
Authority
MA
Morocco
Prior art keywords
solid tumor
treatment methods
tumor treatment
ccr2 antagonists
ccr2
Prior art date
Application number
MA050423A
Other languages
English (en)
Inventor
James J Campbell
Samuel Hwang
Rajinder Singh
Xuesong Wu
Original Assignee
Chemocentryx Inc
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc, Univ California filed Critical Chemocentryx Inc
Publication of MA50423A publication Critical patent/MA50423A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA050423A 2018-01-08 2019-01-07 Procédés de traitement de tumeurs solides au moyen d'antagonistes du ccr2 MA50423A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862614923P 2018-01-08 2018-01-08

Publications (1)

Publication Number Publication Date
MA50423A true MA50423A (fr) 2020-08-26

Family

ID=67139234

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050423A MA50423A (fr) 2018-01-08 2019-01-07 Procédés de traitement de tumeurs solides au moyen d'antagonistes du ccr2

Country Status (10)

Country Link
US (2) US11154556B2 (fr)
EP (1) EP3737367A4 (fr)
JP (1) JP7442141B2 (fr)
CN (1) CN112105353B (fr)
AU (1) AU2019205784A1 (fr)
CA (1) CA3087765A1 (fr)
IL (1) IL275898A (fr)
MA (1) MA50423A (fr)
TW (1) TW201938160A (fr)
WO (1) WO2019136368A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020003192A (es) 2017-09-25 2020-07-29 Chemocentryx Inc Terapia de combinacion usando un antagonista del receptor de quimiocina tipo 2 (ccr2) y un inhibidor de pd-1/pd-l1.
US20190269664A1 (en) 2018-01-08 2019-09-05 Chemocentryx, Inc. Methods of treating solid tumors with ccr2 antagonists

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1296978A2 (fr) 2000-06-30 2003-04-02 Bristol-Myers Squibb Company N-ureidoheterocycloaklyl-piperidines utilises comme modulateurs de l'activite du recepteur de la chimiokine
CA2419194C (fr) 2000-08-17 2007-10-16 Lihu Yang Modulateurs cyclopentyles de l'activite du recepteur de la chimiokine
ATE319703T1 (de) 2001-07-02 2006-03-15 Piperidinverbindungen, die sich als modulatoren der chemokinrezeptoraktivität eignen
US20060030582A1 (en) 2002-04-29 2006-02-09 Demartino Julie Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
PT1501507E (pt) 2002-04-29 2008-08-12 Merck Sharp & Dohme Tetrahidropiranil ciclopentil tetrahidropiridopiridinas moduladoras da actividade dos receptores de quimioquinas
WO2003093231A2 (fr) 2002-04-29 2003-11-13 Merck & Co., Inc. Modulateurs de l'activite des recepteurs des chimiokines a base de tetrahydropyranyl cyclopentyl tetrahydroisoquinoline
MY129850A (en) 2002-04-29 2007-05-31 Merck Sharp & Dohme Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
US7491737B2 (en) 2002-10-30 2009-02-17 Merck & Co., Inc. Heterarylpiperidine modulators of chemokine receptor activity
WO2004076411A2 (fr) 2003-02-24 2004-09-10 Merck & Co., Inc. Modulateurs d'heterotricylicamide fusionne avec un aminocyclopentyl de l'activite des recepteurs de la chimiokine
CA2519220A1 (fr) 2003-03-18 2004-09-30 Merck & Co., Inc. Modulateurs amino cyclobutylamide de l'activite du recepteur de chimiokine
AU2004231087B2 (en) 2003-04-15 2007-01-04 Merck Sharp & Dohme Corp. Benzoxazinyl-amidocyclopentyl-heterocyclic modulators of chemokine receptors
JP2006523704A (ja) 2003-04-17 2006-10-19 メルク　エンド　カムパニー　インコーポレーテッド ケモカイン受容体活性ヘテロサイクリックシクロペンチルテトラヒドロイソキノリンおよびテトラヒドロピリドピリジンのモジュレーター
US20060205761A1 (en) 2003-06-06 2006-09-14 Catherine Abbadie Ccr-2 antagonists for treatment of neuropathic pain
BRPI0415836A (pt) 2003-10-27 2007-01-02 Merck & Co Inc composto, métodos para a modulação da atividade de receptor de quimocina em um mamìfero, e para o tratamento, a melhoria, o controle ou a redução do risco de uma doença ou distúrbio inflamatório e imunorregulatório, e de artrite reumatóide, composição farmacêutica
AR045875A1 (es) 2003-10-27 2005-11-16 Merck & Co Inc Procedimiento para la preparacion del antagonista ccr-2
AU2004313486A1 (en) 2004-01-02 2005-07-28 Merck & Co., Inc. Alkylamino, arylamino, and sulfonamido cyclopentyl amide modulators of chemokine receptor activity
US7700772B2 (en) 2004-02-12 2010-04-20 Merck Sharp & Dohme Corp. Amino heterocyclic modulators of chemokine receptor activity
JP2007537264A (ja) 2004-05-11 2007-12-20 インサイト コーポレイション ケモカインレセプタのモジュレータとしての３−（４−ヘテロアリールシクロヘキシルアミノ）シクロペンタンカルボキサミド
PA8653301A1 (es) 2004-11-22 2006-11-09 Incyte Corp Incyte Corp Sales de la n-[2-({(3r)-1-[trans-4-hidroxi-4-(6-metoxipiridin-3-il) ciclohexil)pirrolidin
AU2006204038A1 (en) 2005-01-06 2006-07-13 Merck & Co., Inc. Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders
US8519135B2 (en) 2006-07-14 2013-08-27 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2/CCR9
US7671062B2 (en) 2006-07-28 2010-03-02 Bristol-Myers Squibb Company Modulators of chemokine receptor activity, crystalline forms and process
AU2008266951B2 (en) 2007-06-18 2013-12-12 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor PD-1
CA2692761C (fr) 2007-07-12 2013-04-30 Chemocentryx, Inc. Heteroaryl-pyridyl- et phenyl-benzenesulfonamides condenses en tant que modulateurs du ccr2 pour le traitement de l'inflammation
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
DK2342226T3 (en) 2008-09-26 2016-09-26 Dana Farber Cancer Inst Inc HUMAN ANTI-PD-1, PD-L1 AND PD-L2 ANTIBODIES AND APPLICATIONS THEREOF
BRPI0923237A2 (pt) 2008-12-10 2019-09-24 Janssen Pharmaceutica Nv compostos de 4-azetidinil-1-heteroaril-ciclohexanol antagonistas de ccr2
JP5844159B2 (ja) 2009-02-09 2016-01-13 ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用
NZ595431A (en) 2009-04-16 2013-12-20 Janssen Pharmaceutica Nv 4-azetidinyl-1-heteroaryl-cyclohexane antagonists of ccr2
CA2758934A1 (fr) 2009-04-17 2010-10-21 Janssen Pharmaceutica Nv Antagonistes de ccr2 a base de 4-azetidinyl-1-phenyl-cyclohexane
EA024397B1 (ru) 2009-12-17 2016-09-30 Сентрекшн Терапьютикс Корпорейшн Новые антагонисты рецептора ccr2 и их применение
US9040526B2 (en) 2010-02-09 2015-05-26 Bristol-Myers Squibb Company Benzylpyrrolidinone derivatives as modulators of chemokine receptor activity
EP2569298B1 (fr) 2010-05-12 2015-11-25 Boehringer Ingelheim International GmbH Nouveaux antagonistes du récepteur ccr2, son procédé de production et utilisation associée en tant que médicaments
US8642622B2 (en) 2010-06-16 2014-02-04 Bristol-Myers Squibb Company Piperidinyl compound as a modulator of chemokine receptor activity
JP5936608B2 (ja) 2010-06-17 2016-06-22 ヤンセン ファーマシューティカ エヌ．ベー． Ｃｃｒ２のシクロヘキシル−アゼチジニルアンタゴニスト
AU2012226890B2 (en) 2011-03-10 2016-10-06 Daiichi Sankyo Company, Limited Dispiropyrrolidine derivative
KR101981873B1 (ko) 2011-11-28 2019-05-23 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
US8822460B2 (en) 2012-04-06 2014-09-02 Janssen Pharmaceutica Nv Fused cyclopentyl antagonists of CCR2
CN104470949A (zh) 2012-05-15 2015-03-25 百时美施贵宝公司 通过破坏pd-1/pd-l1信号传输的免疫治疗
EP2855528B1 (fr) 2012-05-31 2019-06-19 Genentech, Inc. Procédés de traitement du cancer au moyen d'antagonistes liant l'axe pd-1 et d'antagonistes de vegf
EP2864358B1 (fr) 2012-06-22 2019-08-07 Sorrento Therapeutics, Inc. Protéines de liaison à un antigène qui se lient à ccr2
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
BR112015031073B1 (pt) * 2013-06-21 2022-11-29 Zenith Epigenetics Ltd Compostos inibidores bicíclicos de bromodomínio e composição farmacêutica contendo os referidos compostos
ES2827679T3 (es) 2013-08-20 2021-05-24 Merck Sharp & Dohme Tratamiento del cáncer con una combinación de un antagonista de PD-1 y dinaciclib
AU2014315457B2 (en) 2013-09-04 2018-05-10 Bristol-Myers Squibb Company Compounds useful as immunomodulators
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
US9850225B2 (en) 2014-04-14 2017-12-26 Bristol-Myers Squibb Company Compounds useful as immunomodulators
TN2017000084A1 (en) 2014-09-11 2018-07-04 Bristol Myers Squibb Co Macrocyclic inhibitors of the pd-1/pd-l1 and cd80 (b7-1)/pd-li protein/protein interactions
US9732119B2 (en) 2014-10-10 2017-08-15 Bristol-Myers Squibb Company Immunomodulators
US9856292B2 (en) 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
US9861680B2 (en) 2014-12-18 2018-01-09 Bristol-Myers Squibb Company Immunomodulators
US9944678B2 (en) 2014-12-19 2018-04-17 Bristol-Myers Squibb Company Immunomodulators
US20160222060A1 (en) 2015-02-04 2016-08-04 Bristol-Myers Squibb Company Immunomodulators
US9809625B2 (en) 2015-03-18 2017-11-07 Bristol-Myers Squibb Company Immunomodulators
EP3297438B1 (fr) * 2015-05-21 2021-10-20 ChemoCentryx, Inc. Modulateurs du ccr2
WO2017165125A1 (fr) * 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Utilisation d'un antagoniste de pd-1 et d'un anticorps anti-ccr2 dans le traitement du cancer
US10195188B2 (en) 2016-06-13 2019-02-05 Chemocentryx, Inc. Method of treating pancreatic cancer
US10251888B2 (en) 2016-06-13 2019-04-09 Chemocentryx, Inc. Method of treating pancreatic cancer
CA3029256A1 (fr) * 2016-06-27 2018-01-04 Chemocentryx, Inc. Composes immunomodulateurs
MX2020003192A (es) 2017-09-25 2020-07-29 Chemocentryx Inc Terapia de combinacion usando un antagonista del receptor de quimiocina tipo 2 (ccr2) y un inhibidor de pd-1/pd-l1.
US20190275015A1 (en) 2017-09-25 2019-09-12 Chemocentryx, Inc. Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1/pd-l1 inhibitor
US20190269664A1 (en) 2018-01-08 2019-09-05 Chemocentryx, Inc. Methods of treating solid tumors with ccr2 antagonists

Also Published As

Publication number Publication date
EP3737367A4 (fr) 2022-11-09
CA3087765A1 (fr) 2019-07-11
EP3737367A2 (fr) 2020-11-18
US20190209573A1 (en) 2019-07-11
JP7442141B2 (ja) 2024-03-04
JP2021509678A (ja) 2021-04-01
IL275898A (en) 2020-08-31
US20220241290A1 (en) 2022-08-04
CN112105353B (zh) 2024-04-19
TW201938160A (zh) 2019-10-01
AU2019205784A1 (en) 2020-07-30
WO2019136368A3 (fr) 2020-04-16
US11154556B2 (en) 2021-10-26
WO2019136368A2 (fr) 2019-07-11
CN112105353A (zh) 2020-12-18

Similar Documents

Publication Publication Date Title
MA47206A (fr) Méthodes de traitement du cancer au moyen d'anticorps anti-tim-3
MA51796A (fr) Procédés et compositions pour l'administration de protéines thérapeutiques
MA47208A (fr) Procédés de traitement du cancer à l'aide d'anticorps anti-pd-1
MA45192A (fr) Traitement d'association
MA54609A (fr) Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer
MA56050A (fr) Inhibiteurs hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer
MA54608A (fr) Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer
MA55629A (fr) Compositions d'anticorps pour le traitement de tumeurs
MA50849A (fr) Substances et procédés pour le traitement d'hémoglobinopathies
MA45341A (fr) Procédés de traitement de malignités de lymphocytes b au moyen d'une thérapie cellulaire adoptive
MA49069A (fr) Procédés et compositions pour le traitement d'apnée du sommeil
MA45798A (fr) Compositions et procédés d'inhibition de masp-3 pour le traitement de maladies et troubles divers
MA43283A (fr) Procédés et compositions pour le traitement du cancer
MA55560A (fr) Dérivés d'amide n-hétéroaromatiques destinés au traitement du cancer
MA53558A (fr) Compositions et procédés pour le traitement d'infections virales
MA47613A (fr) Compositions et procédés de traitement du cancer
MA46842A (fr) Méthodes de traitement de l'obésité au moyen d'anticorps anti-angptl8
MA53873A (fr) Compositions et procédés pour le traitement de la presbytie
MA53445A (fr) Procédés et compositions pour la modification de plantes
MA52657A (fr) Anticorps spécifiques d'axl pour le traitement du cancer
MA52630A (fr) Procédés de traitement de l'hémophilie a
MA45552A (fr) Compositions destinées au traitement de l'amylose
MA54909A (fr) Procédés et appareil de traitement d'eau
MA43758A (fr) Procédés pour déterminer le dosage d'un agent thérapeutique et traitements associés
MA50423A (fr) Procédés de traitement de tumeurs solides au moyen d'antagonistes du ccr2